PROPANC BIOPHARMA INC

Propanc Biopharma’s journey highlights the high‑risk, high‑reward nature of biotech, as it battles financial woes while developing proenzyme therapy for pancreatic and colorectal cancer.

Propanc Biopharma’s stock has experienced a dramatic rollercoaster ride, plummeting from a 52-week high of $222 to a low of $1.25, amidst concerns over the company’s financial health and the high-risk, high-reward nature of its biotech endeavors.